

CLINICAL PRACTICE GUIDELINE: EXECUTIVE SUMMARY

# 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary



A Report of the American College of Cardiology/American Heart Association  
Joint Committee on Clinical Practice Guidelines

**Writing  
Committee  
Members\***

Jennifer S. Lawton, MD, FAHA, *Chair*†  
Jacqueline E. Tamis-Holland, MD, FAHA, FACC, FSCAI,  
*Vice Chair*†

Sripal Bangalore, MD, MHA, FACC, FAHA, FSCAI†  
Eric R. Bates, MD, FACC, FAHA†  
Theresa M. Beckie, PhD, FAHA†  
James M. Bischoff, MEd†  
John A. Bittl, MD, FACC, FAHA†  
Mauricio G. Cohen, MD, FACC, FSCAI‡  
J. Michael DiMaio, MD†  
Creighton W. Don, MD, PhD, FACC||  
Stephen E. Fremes, MD, FACC  
Mario F. Gaudino, MD, PhD, MSCE, FACC, FAHA†  
Zachary D. Goldberger, MD, FACC, FAHA†  
Michael C. Grant, MD, MSE†  
Jang B. Jaswal, MS†

Paul A. Kurlansky, MD, FACC†  
Roxana Mehran, MD, FACC†  
Thomas S. Metkus Jr, MD, FACC†  
Lorraine C. Nnacheta, DrPH, MPH†  
Sunil V. Rao, MD, FACC†  
Frank W. Sellke, MD, FACC, FAHA†  
Garima Sharma, MD, FACC†  
Celina M. Yong, MD, MBA, MSc, FSCAI, FACC, FAHA†  
Brittany A. Zwischenberger, MD†

\*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see [Appendix 1](#) of the full-text guideline for detailed information. †ACC/AHA Representative. ‡ACC/AHA Joint Committee on Clinical Practice Guidelines Liaison. §ACC/AHA Task Force on Clinical Data Standards Representative. ||SCAI Representative.

This document was approved by the American College of Cardiology Clinical Policy Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, the American Heart Association Executive Committee, and the Society for Cardiovascular Angiography and Interventions Executive Committee in August 2021.

The American College of Cardiology requests that this document be cited as follows: Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Grant MC, Goldberger ZD, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2022;79:197-215.

This article has been co-published in *Circulation*.

Copies: This document is available on the websites of the American College of Cardiology ([www.acc.org](http://www.acc.org)), and the American Heart Association ([professional.heart.org](http://professional.heart.org)). For copies of this document, please contact the Elsevier Inc. Reprint Department via fax (212-633-3820) or e-mail ([reprints@elsevier.com](mailto:reprints@elsevier.com)).

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology. Requests may be completed online via the Elsevier website (<https://www.elsevier.com/about/policies/copyright/permissions>).

**ACC/AHA Joint Committee Members**

Patrick T. O’Gara, MD, MACC, FAHA, *Chair*  
 Joshua A. Beckman, MD, MS, FAHA, *Chair-Elect*  
 Glenn N. Levine, MD, FACC, FAHA, *Immediate Past Chair*

Sana M. Al-Khatib, MD, MHS, FACC, FAHA  
 Anastasia L. Armbruster, PharmD, FACC  
 Kim K. Birtcher, PharmD, MS, AACC  
 Joaquin E. Cigarroa, MD, FACC  
 Anita Deswal, MD, MPH, FACC, FAHA  
 Dave L. Dixon, PharmD, FACC  
 Lee A. Fleisher, MD, FACC, FAHA  
 Lisa de las Fuentes, MD, MS, FAHA  
 Federico Gentile, MD, FACC  
 Zachary D. Goldberger, MD, FACC, FAHA  
 Bulent Gorenek, MD, FACC  
 Norrisa Haynes, MD, MPH  
 Adrian F. Hernandez, MD, MHS

Mark A. Hlatky, MD, FACC, FAHA  
 José A. Joglar, MD, FACC, FAHA  
 W. Schuyler Jones, MD, FACC  
 Joseph E. Marine, MD, FACC  
 Daniel B. Mark, MD, MPH, FACC, FAHA  
 Debabrata Mukherjee, MD, FACC, FAHA, FSCAI  
 Latha P. Palaniappan, MD, MS, FAHA, FACC  
 Mariann R. Piano, RN, PhD, FAHA  
 Tanveer Rab, MD, FACC  
 Erica S. Spatz, MD, MS, FACC  
 Jacqueline E. Tamis-Holland, MD, FAHA, FACC, FSCAI  
 Duminda N. Wijeyesundera, MD, PhD  
 Y. Joseph Woo, MD, FAHA, FACC

¶Former Joint Committee member; current member during the writing effort.

**ABSTRACT**

**AIM** The executive summary of the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions coronary artery revascularization guideline provides the top 10 items readers should know about the guideline. In the full guideline, the recommendations replace the 2011 coronary artery bypass graft surgery guideline and the 2011 and 2015 percutaneous coronary intervention guidelines. This summary offers a patient-centric approach to guide clinicians in the treatment of patients with significant coronary artery disease undergoing coronary revascularization, as well as the supporting documentation to encourage their use.

**METHODS** A comprehensive literature search was conducted from May 2019 to September 2019, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, CINHL Complete, and other relevant databases. Additional relevant studies, published through May 2021, were also considered.

**STRUCTURE** Recommendations from the earlier percutaneous coronary intervention and coronary artery bypass graft surgery guidelines have been updated with new evidence to guide clinicians in caring for patients undergoing coronary revascularization. This summary includes recommendations, tables, and figures from the full guideline that relate to the top 10 take-home messages. The reader is referred to the full guideline for graphical flow charts, supportive text, and tables with additional details about the rationale for and implementation of each recommendation, and the evidence tables detailing the data considered in the development of this guideline.

**TOP 10 TAKE-HOME MESSAGES**

1. Treatment decisions regarding coronary revascularization in patients with coronary artery disease (CAD) should be based on clinical indications, regardless of sex, race, or ethnicity, because there is no evidence that some patients benefit less than others, and efforts to reduce disparities of care are warranted.
2. In patients being considered for coronary revascularization for whom the optimal treatment strategy is unclear, a multidisciplinary Heart Team approach is recommended. Treatment decisions should be patient centered, incorporate patient preferences and goals, and include shared decision-making.
3. For patients with significant left main disease, surgical revascularization is indicated to improve survival relative to that likely to be achieved with medical therapy. Percutaneous revascularization is a reasonable option to improve survival, compared with medical therapy, in selected patients with low-to-medium anatomic complexity of CAD and left main disease that is equally suitable for surgical or percutaneous revascularization.
4. Updated evidence from contemporary trials supplement older evidence with regard to mortality benefit of revascularization in patients with stable ischemic heart disease, normal left ventricular ejection fraction, and triple-vessel CAD. Surgical revascularization

may be reasonable to improve survival. A survival benefit with percutaneous revascularization is uncertain. Revascularization decisions are based on consideration of disease complexity, technical feasibility of treatment, and a Heart Team discussion.

5. The use of a radial artery as a surgical revascularization conduit is preferred versus the use of a saphenous vein conduit to bypass the second most important target vessel with significant stenosis after the left anterior descending coronary artery. Benefits include superior patency, reduced adverse cardiac events, and improved survival.
6. Radial artery access is recommended in patients undergoing percutaneous intervention who have acute coronary syndrome or stable ischemic heart disease, to reduce bleeding and vascular complications compared with a femoral approach. Patients with acute coronary syndrome also benefit from a reduction in mortality rate with this approach.
7. A short duration of dual antiplatelet therapy after percutaneous revascularization in patients with stable ischemic heart disease is reasonable to reduce the risk of bleeding events. After consideration of recurrent ischemia and bleeding risks, select patients may safely transition to P2Y12 inhibitor monotherapy and stop aspirin after 1 to 3 months of dual antiplatelet therapy.
8. Staged percutaneous intervention (while in hospital or after discharge) of a significantly stenosed nonculprit artery in patients presenting with an ST-segment-elevation myocardial infarction is recommended in select patients to improve outcomes. Percutaneous intervention of the nonculprit artery at the time of primary percutaneous coronary intervention is less clear and may be considered in stable patients with uncomplicated revascularization of the culprit artery, low-complexity nonculprit artery disease, and normal renal function. In contrast, percutaneous intervention of the nonculprit artery can be harmful in patients in cardiogenic shock.
9. Revascularization decisions in patients with diabetes and multivessel CAD are optimized by the use of a Heart Team approach. Patients with diabetes who have triple-vessel disease should undergo surgical revascularization; percutaneous coronary intervention may be considered if they are poor candidates for surgery.
10. Treatment decisions for patients undergoing surgical revascularization of CAD should include the calculation of a patient's surgical risk with the Society of Thoracic Surgeons score. The usefulness of the SYNTAX (Synergy Between PCI With TAXUS and Cardiac Surgery) score calculation in treatment decisions is less clear because of the interobserver variability in its calculation and its absence of clinical variables.

## PURPOSE OF THE EXECUTIVE SUMMARY

---

This executive summary provides the reader with the Top 10 items they should know about the American College of Cardiology (ACC)/American Heart Association (AHA)/Society for Cardiovascular Angiography and Interventions 2021 coronary artery revascularization guideline (1) and includes the justification of those updates, as well as the consolidation of the 2011 coronary artery bypass graft (CABG) and the 2011 and 2015 percutaneous coronary intervention (PCI) guidelines, with the added consideration of using a patient-centric disease approach (1). The full guideline (1) provides the most up-to-date evidence to direct the clinician in patient decision-making. The intended primary target audience consists of cardiovascular clinicians who are involved in the care of patients for whom revascularization is considered or indicated. CAD is to be approached with the most current treatment options and treated as a “condition.”

The scope of the full text “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization” (1) updates and consolidates 3 previously published guidelines (2-4) and replaces applicable sections on revascularization in 3 other guidelines (5-7), with the added consideration of using a patient-centric disease approach. The 2021 guideline replaces these documents/sections:

1. Replace/retire the 2011 PCI guideline (2).
2. Replace/retire the 2011 CABG guideline (3).
3. Replace/retire the 2015 update in PCI in ST-segment-elevation myocardial infarction (STEMI) guideline (4).
4. Replace/retire 2013 STEMI guideline, Sections 4.1, 4.2, 4.3, 4.4, 5.3 (deals with transfer after lytic with intent to do PCI) 6.2, 6.4, 7.1, and 7.2 (6).
5. Replace/retire 2014 non-ST-segment-elevation acute coronary syndrome guideline, Sections 4.4.4, 5.1.1, 5.1.2.1, 5.1.2.2, 5.1.2.3, and 5.2 (7).
6. Replace/retire 2012 stable ischemic heart disease (SIHD) guideline, Section 5 (5).

## DOCUMENT REVIEW AND APPROVAL

---

The full guideline was reviewed by 2 official reviewers each nominated by the ACC and AHA; 1 reviewer each from the ACC, AHA, Society of Thoracic Surgeons, American Association for Thoracic Surgery, and the Society for Cardiovascular Angiography and Interventions; and 31 individual content reviewers. Authors' relationships with industry and other entities information is published in [Appendix 1](#) of the full guideline (1). Reviewers' relationships with industry and other entities information is published in [Appendix 2](#) of the full guideline (1).

**CLASS OF RECOMMENDATION AND  
LEVEL OF EVIDENCE**

The Class of Recommendation (COR) indicates the strength of recommendation, encompassing the

estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates the quality of scientific evidence supporting the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (**Table 1**) (8).

**TABLE 1** Applying ACC/AHA Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care (Updated May 2019)\*

CLASS (STRENGTH) OF RECOMMENDATION	LEVEL (QUALITY) OF EVIDENCE†‡
<b>CLASS 1 (STRONG)</b> <span style="float: right;"><b>Benefit &gt;&gt;&gt; Risk</b></span>  <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>• Is recommended</li> <li>• Is indicated/useful/effective/beneficial</li> <li>• Should be performed/administered/other</li> <li>• Comparative-Effectiveness Phrases†:               <ul style="list-style-type: none"> <li>– Treatment/strategy A is recommended/indicated in preference to treatment B</li> <li>– Treatment A should be chosen over treatment B</li> </ul> </li> </ul>	<b>LEVEL A</b>  <ul style="list-style-type: none"> <li>• High-quality evidence‡ from more than 1 RCT</li> <li>• Meta-analyses of high-quality RCTs</li> <li>• One or more RCTs corroborated by high-quality registry studies</li> </ul>
<b>CLASS 2a (MODERATE)</b> <span style="float: right;"><b>Benefit &gt;&gt; Risk</b></span>  <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>• Is reasonable</li> <li>• Can be useful/effective/beneficial</li> <li>• Comparative-Effectiveness Phrases†:               <ul style="list-style-type: none"> <li>– Treatment/strategy A is probably recommended/indicated in preference to treatment B</li> <li>– It is reasonable to choose treatment A over treatment B</li> </ul> </li> </ul>	<b>LEVEL B-R</b> <span style="float: right;"><b>(Randomized)</b></span>  <ul style="list-style-type: none"> <li>• Moderate-quality evidence‡ from 1 or more RCTs</li> <li>• Meta-analyses of moderate-quality RCTs</li> </ul>
<b>CLASS 2b (WEAK)</b> <span style="float: right;"><b>Benefit ≥ Risk</b></span>  <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>• May/might be reasonable</li> <li>• May/might be considered</li> <li>• Usefulness/effectiveness is unknown/unclear/uncertain or not well-established</li> </ul>	<b>LEVEL B-NR</b> <span style="float: right;"><b>(Nonrandomized)</b></span>  <ul style="list-style-type: none"> <li>• Moderate-quality evidence‡ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies</li> <li>• Meta-analyses of such studies</li> </ul>
<b>CLASS 3: No Benefit (MODERATE)</b> <span style="float: right;"><b>Benefit = Risk</b></span> <b>(Generally, LOE A or B use only)</b>  <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>• Is not recommended</li> <li>• Is not indicated/useful/effective/beneficial</li> <li>• Should not be performed/administered/other</li> </ul>	<b>LEVEL C-LD</b> <span style="float: right;"><b>(Limited Data)</b></span>  <ul style="list-style-type: none"> <li>• Randomized or nonrandomized observational or registry studies with limitations of design or execution</li> <li>• Meta-analyses of such studies</li> <li>• Physiological or mechanistic studies in human subjects</li> </ul>
<b>Class 3: Harm (STRONG)</b> <span style="float: right;"><b>Risk &gt; Benefit</b></span>  <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>• Potentially harmful</li> <li>• Causes harm</li> <li>• Associated with excess morbidity/mortality</li> <li>• Should not be performed/administered/other</li> </ul>	<b>LEVEL C-EO</b> <span style="float: right;"><b>(Expert Opinion)</b></span>  <ul style="list-style-type: none"> <li>• Consensus of expert opinion based on clinical experience</li> </ul>

COR and LOE are determined independently (any COR may be paired with any LOE).

A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

\* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR 1 and 2a; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely-used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.

### TAKE-HOME MESSAGE NO. 1

Treatment decisions regarding coronary revascularization in patients with CAD should be based on clinical

indications regardless of sex, race, or ethnicity, because there is no evidence that some patients benefit less than others, and efforts to reduce disparities of care are warranted.

#### Recommendation to Improve Equity of Care in Revascularization Referenced studies that support the recommendation are summarized in [Online Data Supplement 1](#).

COR	LOE	RECOMMENDATION
1	B-NR	1. In patients who require coronary revascularization, treatment decisions should be based on clinical indication, regardless of sex (9-15), or race or ethnicity (16-18), and efforts to reduce disparities of care are warranted (19,20).

### TAKE-HOME MESSAGE NO. 2

In patients being considered for coronary revascularization for whom the optimal treatment strategy is unclear, a

multidisciplinary Heart Team approach is recommended. Treatment decisions should be patient-centered, incorporate patient preferences and goals, and include shared decision-making.

#### Recommendation for the Heart Team Referenced studies that support the recommendation are summarized in [Online Data Supplement 2](#).

COR	LOE	RECOMMENDATION
1	B-NR	1. In patients where the optimal treatment strategy is unclear, a Heart Team approach that includes representatives from interventional cardiology, cardiac surgery, and clinical cardiology is recommended to improve patient outcomes (21-26).


#### Recommendations for Shared Decision-Making and Informed Consent Referenced studies that support the recommendation are summarized in [Online Data Supplement 2](#).

COR	LOE	RECOMMENDATION
1	C-LD	1. In patients undergoing revascularization, decisions should be patient-centered—that is, considerate of the patient's preferences and goals, cultural beliefs, health literacy, and social determinants of health—and made in collaboration with the patient's support system (27,28).
1	C-LD	2. In patients undergoing coronary angiography or revascularization, adequate information about benefits, risks, therapeutic consequences, and potential alternatives in the performance of percutaneous and surgical myocardial revascularization should be given, when feasible, with sufficient time for informed decision-making to improve clinical outcomes (29-31).

Ideal situations for Heart Team consideration include patients with complex coronary disease, comorbid conditions that could impact the success of the revascularization strategy, and other clinical or social situations that may impact outcomes (Figure 1 and Table 2). Shared decision-making (Figure 2) is a collaborative approach that provides patients with unbiased, evidence-based

information on treatment choices and encourages a dialogue with patients and providers to make decisions that use scientific evidence and align with the patient's values and preferences (29,30,32). Procedure-related and long-term risks and benefits such as survival, quality of life, and the need for late reintervention should be included in such discussions (Table 3) (33).





**TABLE 2 Factors for Consideration by the Heart Team**

**Coronary Anatomy**

- Left main disease
- Multivessel disease
- High anatomic complexity (i.e., bifurcation disease, high SYNTAX score)

**Comorbidities**

- Diabetes
- Systolic dysfunction
- Coagulopathy
- Valvular heart disease
- Frailty
- Malignant neoplasm
- End-stage renal disease
- Chronic obstructive pulmonary disease
- Immunosuppression
- Debilitating neurological disorders
- Liver disease/cirrhosis
- Prior CVA
- Calcified/porcelain aorta
- Aortic aneurysm

**TABLE 2 Continued**

**Procedural Factors**


- Local and regional outcomes
- Access site for PCI
- Surgical risk
- PCI risk

**Patient Factors**

- Unstable presentation or shock
- Patient preferences
- Inability or unwillingness to adhere to DAPT
- Patient social support
- Religious beliefs
- Patient education, knowledge, and understanding

CVA indicates cerebrovascular accident; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention; and SYNTAX, Synergy Between PCI With TAXUS and Cardiac Surgery.

*continued in the next column*



**TABLE 3 Ideal Components of the Shared Decision-Making and Informed Consent Process**

**Patient-Centered Care**

- Assess a patient's ability to understand complex health information
- Seek support of family/others
- Elicit and respect cultural, racial, ethnic, or religious preferences and values
- Evaluate social determinants of health (education, income, access to health care)
- Improve telephone/telemedicine access
- Discuss treatment alternatives and how each affects the patient's quality of life

**Shared Decision-Making**

- Encourage questions and explain the patient's role in the decision-making partnership
- Clearly and accurately communicate the potential risks and benefits of a particular procedure and alternative treatments
- Ensure that patients have a key role in deciding what revascularization approach is appropriate
- Use shared decision aids:
  - Alphabetical List of Decision Aids by Health Topic, Ottawa Hospital Research Institute (<https://decisionaid.ohri.ca/implement.html>) (34)
  - SHARE Approach Curriculum Tools, Agency for Healthcare Research and Quality (<https://www.ahrq.gov/health-literacy/curriculum-tools/shareddecisionmaking/tools/tool-1/index.html>) (35)
- Spend sufficient time to engage in shared decision-making; allow for a second opinion
- Work with a chaplain, social worker, or other team members to facilitate shared decision-making
- Encourage patients to share their fears, stress, or other emotions, and address appropriately
- Negotiate decision in partnership with the patient and family members
- Respect patient's autonomy to decline recommended treatment

Continued on the next page

**TABLE 3 Continued**

**Consent Procedures**

Use plain language, avoiding jargon, and adopt the patient's words; integrate pictures to teach
Document teach-back of patient's knowledge and understanding
Conduct conversations with a trained interpreter, as needed
Provide patient-specific short- and long-term risks, benefits, and alternative treatments
Provide unbiased, evidence-based, reliable, accessible, and relevant information to patient
Discuss specific risks and benefits with regard to survival, relief of angina, quality of life, and potential additional intervention, as well as uncertainties associated with different treatment strategies
Provide patient time to reflect on the trade-offs imposed by the outcome estimates
Provide information on the level of operator expertise, volume of the facility, and local results in the performance of coronary revascularization options
Clearly inform of the need for continued medical therapy and lifestyle modifications

**TAKE-HOME MESSAGE NO. 3**

For patients with significant left main disease, surgical revascularization is indicated to improve survival relative to that likely to be achieved with medical therapy.

Percutaneous revascularization is a reasonable option to improve survival, compared with medical therapy, in selected patients with low to medium anatomic complexity of CAD and left main disease that is equally suitable for surgical or percutaneous revascularization.

**Recommendations for Revascularization to Improve Survival in SIHD Compared With Medical Therapy**  
Referenced studies that support the recommendations are summarized in [Online Data Supplement 10](#).


COR	LOE	RECOMMENDATIONS
1	B-R	1. In patients with SIHD and significant left main stenosis, CABG is recommended to improve survival (36-39).
2a	B-NR	2. In selected patients with SIHD and significant left main stenosis for whom PCI can provide equivalent revascularization to that possible with CABG, PCI is reasonable to improve survival (36).

Studies have shown that CABG confers a survival benefit over medical therapy in multiple subsets of

patients, including left main CAD (**Figure 3**) (36-39), triple vessel CAD (40), and ischemic cardiomyopathy (41-49).



**FIGURE 3** Revascularization in Patients With Stable Ischemic Heart Disease



Colors correspond to [Table 1](#). CABG indicates coronary artery bypass graft; CAD, coronary artery disease; EF, ejection fraction; GDMT, guideline-directed medical therapy; PCI, percutaneous coronary intervention; and SIHD, stable ischemic heart disease. This algorithm summarizes the recommendations in this guideline for the care of patients with stable CAD. It is not meant to encompass every patient scenario or situation, and clinicians are encouraged to use a Heart Team approach when care decisions are unclear and to see the accompanying supportive text for each recommendation. Additionally, in situations that lack sufficient data to make formal recommendations for care, please see Section 17, “Unanswered Questions and Future Directions,” in the full guideline (1).

**TAKE-HOME MESSAGE NO. 4**

Updated evidence from contemporary trials supplement older evidence with regard to mortality benefit of revascularization in patients with SIHD, normal left ventricular ejection fraction, and triple-vessel CAD.

Surgical revascularization may be reasonable to improve survival. A survival benefit with percutaneous revascularization is uncertain. Revascularization decisions are based on consideration of disease complexity, technical feasibility of treatment, and a Heart Team discussion.

**Recommendations for Revascularization to Improve Survival in SIHD Compared With Medical Therapy**  
Referenced studies that support the recommendations are summarized in [Online Data Supplement 10](#).

COR	LOE	RECOMMENDATIONS
2b	B-R	1. In patients with SIHD, normal ejection fraction, significant stenosis in 3 major coronary arteries (with or without proximal LAD), and anatomy suitable for CABG, CABG may be reasonable to improve survival (37,40,50,51).
2b	B-R	2. In patients with SIHD, normal ejection fraction, significant stenosis in 3 major coronary arteries (with or without proximal LAD), and anatomy suitable for PCI, the usefulness of PCI to improve survival is uncertain (50-60).

**TAKE-HOME MESSAGE NO. 5**

The use of a radial artery as a surgical revascularization conduit is preferred to the use of a saphenous vein conduit to bypass the second most important target vessel with significant stenosis after the left anterior descending

coronary artery. Benefits include superior patency, reduced adverse cardiac events, and improved survival.

When choosing conduits for CABG, both clinical and technical factors (e.g., life expectancy, presence of diabetes, presence of CKD, degree of target stenosis) are considered ([Table 4](#)).

**Recommendation for Bypass Conduits in Patients Undergoing CABG**  
Referenced studies that support the recommendation are summarized in [Online Data Supplement 37](#).

COR	LOE	RECOMMENDATION
1	B-R	1. In patients undergoing isolated CABG, the use of a radial artery is recommended in preference to a saphenous vein conduit to graft the second most important, significantly stenosed, non-LAD vessel to improve long-term cardiac outcomes (61-63).

**TABLE 4 Best Practices for the Use of Bypass Conduits in CABG**

- Objectively assess palmar arch completeness and ulnar compensation before harvesting the radial artery. Use the arm with the best ulnar compensation for radial artery harvesting.
- Use radial artery grafts to target vessels with subocclusive stenoses.
- Avoid the use of the radial artery after transradial catheterization.
- Avoid the use of the radial artery in patients with chronic kidney disease and a high likelihood of rapid progression to hemodialysis.
- Use oral calcium channel blockers for the first postoperative year following radial artery grafting.
- Avoid bilateral percutaneous or surgical radial artery procedures in patients with CAD to preserve the artery for future use.
- Harvest the internal mammary artery using the skeletonization technique to reduce the risk of sternal wound complications.
- Use an endoscopic saphenous vein harvest technique in patients at risk of wound complications.
- Use a no-touch saphenous vein harvest technique in patients at low risk of wound complications.
- Use the skeletonized right gastroepiploic artery to graft right coronary artery target vessels with subocclusive stenosis if the operator is experienced with the use of the artery.

CABG indicates coronary artery bypass graft; and CAD, coronary artery disease.

**TAKE-HOME MESSAGE NO. 6**

Radial artery access is recommended in patients undergoing percutaneous intervention who have acute

coronary syndrome or SIHD, to reduce bleeding and vascular complications compared to a femoral approach. Patients with acute coronary syndrome also benefit from a reduction in mortality rate with this approach.

**Recommendations for Radial and Femoral Approaches for PCI**  
 Referenced studies that support the recommendations are summarized in [Online Data Supplement 23](#).

COR	LOE	RECOMMENDATIONS
1	A	1. In patients with ACS undergoing PCI, a radial approach is indicated in preference to a femoral approach to reduce the risk of death, vascular complications, or bleeding (64-67).
1	A	2. In patients with SIHD undergoing PCI, the radial approach is recommended to reduce access site bleeding and vascular complications (67-70).

**TAKE-HOME MESSAGE NO. 7**

A short duration of dual antiplatelet therapy following percutaneous revascularization in patients with SIHD is reasonable to reduce the risk of bleeding events. After consideration of recurrent ischemia and bleeding risks, select patients may safely transition to P2Y12 inhibitor


monotherapy and stop aspirin after 1-3 months of dual antiplatelet therapy.

Pooled data have demonstrated less bleeding with shorter DAPT (3-6 months) and fewer ischemic events (including stent thrombosis) with longer DAPT (>12 months) (75) ([Figure 4](#)).

**Recommendation for Dual Antiplatelet Therapy in Patients After PCI**  
 Referenced studies that support the recommendation are summarized in [Online Data Supplement 44](#).

COR	LOE	RECOMMENDATION
2a	A	1. In selected patients undergoing PCI, shorter-duration DAPT (1 to 3 months) is reasonable with subsequent transition to P2Y12 inhibitor monotherapy to reduce the risk of bleeding events (71-74).

**FIGURE 4** Use of Dual Antiplatelet Therapy for Patients After PCI



Colors correspond to [Table 1](#). ACS indicates acute coronary syndrome; BMS, bare metal stent; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; P2Y12, platelet adenosine diphosphate P2Y12 receptor; PCI, percutaneous coronary intervention; and SIHD, stable ischemic heart disease. This algorithm is adapted from the 2016 DAPT guideline (76) and includes new recommendations from this guideline for the care of patients with CAD. It is not meant to encompass every patient scenario or situation, and clinicians are encouraged to use a Heart Team approach when care decisions are unclear and to see the accompanying supportive text for each recommendation. Additionally, in situations that lack sufficient data to make formal recommendations for care, please see Section 17, "Unanswered Questions and Future Directions," in the full guideline (1).

**TAKE-HOME MESSAGE NO. 8**

Staged percutaneous intervention (while in hospital or after discharge) of a significantly stenosed nonculprit artery in patients presenting with STEMI is recommended in selected patients to improve outcomes. Percutaneous intervention of the nonculprit artery at the time of pri-

mary PCI is less clear and may be considered in stable patients with uncomplicated revascularization of the culprit artery, low-complexity nonculprit artery disease, and normal renal function. In contrast, percutaneous intervention of the nonculprit artery can be harmful in patients in cardiogenic shock.


**Recommendations for Revascularization of the Noninfarct Artery in Patients With STEMI**  
 Referenced studies that support the recommendations are summarized in [Online Data Supplement 8](#).

COR	LOE	RECOMMENDATIONS
1	A	1. In selected hemodynamically stable patients with STEMI and multivessel disease, after successful primary PCI, staged PCI of a significant noninfarct artery stenosis is recommended to reduce the risk of death or MI (77-80).
2a	C-EO	2. In selected patients with STEMI with complex multivessel noninfarct artery disease, after successful primary PCI, elective CABG is reasonable to reduce the risk of cardiac events.
2b	B-R	3. In selected hemodynamically stable patients with STEMI and low-complexity multivessel disease, PCI of a noninfarct artery stenosis may be considered at the time of primary PCI to reduce cardiac event rates (77,78,81-83).
3: Harm	B-R	4. In patients with STEMI complicated by cardiogenic shock, routine PCI of a noninfarct artery at the time of primary PCI should not be performed because of the higher risk of death or renal failure (84-86).

Revascularization strategies (Figure 5) for patients with STEMI and multivessel disease include multivessel PCI at the time of primary PCI, PCI of the infarct artery only followed by staged PCI of a noninfarct artery, PCI of the

infarct artery only with an ischemia-guided approach to treatment of a noninfarct artery, or PCI of the infarct artery only with elective CABG.

**FIGURE 5** Revascularization of Noninfarct-Related Coronary Artery Lesions in Patients With STEMI



Colors correspond to [Table 1](#). CABG indicates coronary artery bypass graft; GDMT, guideline-directed medical therapy; PCI, percutaneous coronary intervention; and STEMI, ST-segment-elevation myocardial infarction. \*Normal blood pressure and heart rate, left ventricular end-diastolic pressure <20 mm Hg, no chronic renal insufficiency or acute kidney injury, and expected total contrast volume <3× glomerular filtration rate, simple lesion anatomy. †In making the decision about the need for and mode of revascularization the Heart Team should consider the suitability of the non-culprit artery for PCI, the coronary complexity and the risk of revascularization, the extent of myocardium at risk, and patient comorbidities, including life expectancy or other significant patient comorbidities, such as chronic renal insufficiency or acute kidney injury. ‡Staged PCI can be performed in hospital or after discharge, up to 45 days post MI. ¶ Symbol denotes time elapsed before proceeding to the next procedure. This algorithm summarizes the recommendations in this guideline for the care of patients with STEMI and noninfarct artery disease. It is not meant to encompass every patient scenario or situation, and clinicians are encouraged to use a Heart Team approach when care decisions are unclear and to see the accompanying supportive text for each recommendation. Additionally, in situations that lack sufficient data to make formal recommendations for care, please see Section 17, "Unanswered Questions and Future Directions," in the full guideline (1).



**TAKE-HOME MESSAGE NO. 9**

Revascularization decisions in patients with diabetes and multivessel CAD are optimized by the use of a Heart Team

approach. Patients with diabetes who have triple-vessel disease should undergo surgical revascularization; PCI may be considered if they are poor candidates for surgery.

**Recommendations for Patients With Diabetes**  
 Referenced studies that support the recommendations are summarized in [Online Data Supplement 14](#).

COR	LOE	RECOMMENDATIONS
1	A	1. In patients with diabetes and multivessel CAD with involvement of the LAD, who are appropriate candidates for CABG, CABG (with a LIMA to the LAD) is recommended in preference to PCI to reduce mortality and repeat revascularizations (87-94).
2a	B-NR	2. In patients with diabetes, who have multivessel CAD amenable to PCI and an indication for revascularization and are poor candidates for surgery, PCI can be useful to reduce long-term ischemic outcomes (95,96).
2b	B-R	3. In patients with diabetes, who have left main stenosis and low- or intermediate-complexity CAD in the rest of the coronary anatomy, PCI may be considered an alternative to CABG to reduce major adverse cardiovascular outcomes (91,97).

**TAKE-HOME MESSAGE NO. 10**

Treatment decisions for patients undergoing surgical revascularization of CAD should include the calculation of a patient’s surgical risk with the Society of Thoracic

Surgeons score. The usefulness of the SYNTAX score calculation in treatment decisions is less clear because of the interobserver variability in its calculation and its absence of clinical variables.

**Recommendation for Predicting Patient Risk of Death With CABG**  
 Referenced studies that support the recommendation are summarized in [Online Data Supplements 3](#).

COR	LOE	RECOMMENDATION
1	B-NR	1. In patients who are being considered for CABG, calculation of the Society of Thoracic Surgeons risk score is recommended to help stratify patient risk (98,99).

Patients with liver cirrhosis, frailty, and malnutrition have increased perioperative morbidity and mortality after cardiac surgery (100-111) and may be assessed by other tools (Table 5).

**TABLE 5** Assessment of Risk Factors Not Quantified in the STS Score

Risk Factor	Assessment Tool
Cirrhosis	Model for End-Stage Liver Disease (MELD) score (98-100,112-114)
Frailty	Gait speed (102,104-108,110)
Malnutrition	Malnutrition Universal Screening Tool (MUST) (101,103,109,110)

STS indicates Society of Thoracic Surgeons.

**Recommendation for Defining Coronary Artery Lesion Complexity: Calculation of the SYNTAX Score**  
Referenced studies that support the recommendation are summarized in [Online Data Supplement 4](#).

COR	LOE	RECOMMENDATION
2b	B-NR	1. In patients with multivessel CAD, an assessment of CAD complexity such as the SYNTAX score may be useful to guide revascularization (115-118)

Many factors contribute to the estimation of complexity of CAD (Table 6).

**TABLE 6** Angiographic Features Contributing to Increasing Complexity of CAD

Multivessel disease
Left main or proximal LAD artery lesion
Chronic total occlusion
Trifurcation lesion
Complex bifurcation lesion
Heavy calcification
Severe tortuosity
Aorto-ostial stenosis
Diffusely diseased and narrowed segments distal to the lesion
Thrombotic lesion
Lesion length >20 mm

CAD indicates coronary artery disease; and LAD, left anterior descending.

## REFERENCES

- Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2021;00:000-000.
- Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol*. 2011;58:e44-e122.
- Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2011;58:e123-e210.
- Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. *J Am Coll Cardiol*. 2016;67:1235-1250.
- Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2012;60:e44-e164.
- O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;61:485-510.
- Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;64:e139-e228.
- American College of Cardiology and American Heart Association. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. 2010. Accessed May 27, 2021. Available at: <https://www.acc.org/Guidelines/About-Guidelines-and-Clinical-Documents/Methodology> and [https://professional.heart.org/-/media/phd-files/guidelines-and-statements/methodology\\_manual\\_and\\_policies\\_ucm\\_319826.pdf](https://professional.heart.org/-/media/phd-files/guidelines-and-statements/methodology_manual_and_policies_ucm_319826.pdf)
- O'Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. *JAMA*. 2008;300:71-80.
- Lee LC, Poh KK, Tang TPL, et al. The impact of gender on the outcomes of invasive versus conservative management of patients with non-ST-segment elevation myocardial infarction. *Ann Acad Med Singap*. 2010;39:168-172.
- Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy. *Am Heart J*. 2004;147:133-139.
- Heer T, Hochadel M, Schmidt K, et al. Sex differences in percutaneous coronary intervention-insights from the coronary angiography and PCI registry of the German Society of Cardiology. *J Am Heart Assoc*. 2017;6:e004972.
- Tamis-Holland JE, Lu J, Korytkowski M, et al. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization

- Investigation 2 Diabetes). *J Am Coll Cardiol*. 2013;61:1767-1776.
14. Davis KB, Chaitman B, Ryan T, et al. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. *Coronary Artery Surgery Study*. *J Am Coll Cardiol*. 1995;25:1000-1009.
15. Gudnadottir GS, Andersen K, Thrainsdottir IS, et al. Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes. *Am Heart J*. 2017;191:65-74.
16. Golomb M, Redfors B, Crowley A, et al. Prognostic impact of race in patients undergoing PCI: analysis from 10 randomized coronary stent trials. *J Am Coll Cardiol Interv*. 2020;13:1586-1595.
17. Palmeri ST, Lowe AM, Sleeper LA, et al. Racial and ethnic differences in the treatment and outcome of cardiogenic shock following acute myocardial infarction. *Am J Cardiol*. 2005;96:1042-1049.
18. Sabatine MS, Blake GJ, Drazner MH, et al. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. *Circulation*. 2005;111:1217-1224.
19. Cantor JC, DeLia D, Tiedemann A, et al. Reducing racial disparities in coronary angiography. *Health Aff (Millwood)*. 2009;28:1521-1531.
20. Miller CD, Stopyra JP, Mahler SA, et al. ACES (Accelerated Chest Pain Evaluation With Stress Imaging) protocols eliminate testing disparities in patients with chest pain. *Crit Pathw Cardiol*. 2019;18:5-9.
21. Bonzel T, Schächinger V, Dörge H. Description of a Heart Team approach to coronary revascularization and its beneficial long-term effect on clinical events after PCI. *Clin Res Cardiol*. 2016;105:388-400.
22. Chu D, Anastacio MM, Mulukutla SR, et al. Safety and efficacy of implementing a multidisciplinary heart team approach for revascularization in patients with complex coronary artery disease: an observational cohort pilot study. *JAMA Surg*. 2014;149:1109-1112.
23. Leonardi S, Marino M, Crimi G, et al. Appropriateness of percutaneous coronary interventions in patients with ischaemic HEart disease in Italy: the APACHE pilot study. *BMJ Open*. 2017;7:e016909.
24. Pavlidis AN, Perera D, Karamasis GV, et al. Implementation and consistency of heart team decision-making in complex coronary revascularisation. *Int J Cardiol*. 2016;206:37-41.
25. Sanchez CE, Dota A, Badhwar V, et al. Revascularization heart team recommendations as an adjunct to appropriate use criteria for coronary revascularization in patients with complex coronary artery disease. *Catheter Cardiovasc Interv*. 2016;88:e103-e112.
26. Yamasaki M, Abe K, Horikoshi R, et al. Enhanced outcomes for coronary artery disease obtained by a multidisciplinary heart team approach. *Gen Thorac Cardiovasc Surg*. 2019;67:841-848.
27. Lamore K, Montalescot L, Untas A. Treatment decision-making in chronic diseases: what are the family members' roles, needs and attitudes? A systematic review. *Patient Educ Couns*. 2017;100:2172-2181.
28. Stacey D, Bennett CL, Barry MJ, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2011;10:CD001431.
29. Lin GA, Fagerlin A. Shared decision making: state of the science. *Circ Cardiovasc Qual Outcomes*. 2014;7:328-334.
30. Ting HH, Brito JP, Montori VM. Shared decision making: science and action. *Circ Cardiovasc Qual Outcomes*. 2014;7:323-327.
31. Hughes TM, Merath K, Chen Q, et al. Association of shared decision-making on patient-reported health outcomes and healthcare utilization. *Am J Surg*. 2018;216:7-12.
32. Chewning B, Bylund CL, Shah B, et al. Patient preferences for shared decisions: a systematic review. *Patient Educ Couns*. 2012;86:9-18.
33. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J*. 2019;40:87-165.
34. Ottawa Hospital Research Institute. Patient Decision Aids: Implementation Toolkit. 2014. Accessed June 25, 2021. Available at: <https://decisionaid.ohri.ca/Implement.html>
35. Agency for Healthcare Research and Quality. The SHARE Approach—Essential Steps of Shared Decision-making: Quick Reference Guide. 2020. Accessed June 25, 2021. Available at: <https://www.ahrq.gov/health-literacy/curriculum-tools/shareddecisionmaking/tools/tool-1/index.html>
36. Bittl JA, He Y, Jacobs AK, et al. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. *Circulation*. 2013;127:2177-2185.
37. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. *Lancet*. 1994;344:563-570.
38. Takaro T, Peduzzi P, Detre KM, et al. Survival in subgroups of patients with left main coronary artery disease. Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease. *Circulation*. 1982;66:14-22.
39. Talano JV, Scanlon PJ, Meadows WR, et al. Influence of surgery on survival in 145 patients with left main coronary artery disease. *Circulation*. 1975;52(suppl):I105-I111.
40. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. *Lancet*. 1982;2:1173-1180.
41. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. *N Engl J Med*. 2016;374:1511-1520.
42. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery: survival data. *Circulation*. 1983;68:939-950.
43. Hamad MAS, van Straten AHM, Schönberger JPAM, et al. Preoperative ejection fraction as a predictor of survival after coronary artery bypass grafting: comparison with a matched general population. *J Cardiothorac Surg*. 2010;5:29.
44. Jiang L, Xu L, Song L, et al. Comparison of three treatment strategies for patients with triple-vessel coronary disease and left ventricular dysfunction. *J Interv Cardiol*. 2018;31:310-318.
45. Marui A, Kimura T, Nishiwaki N, et al. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions  $\leq 50\%$  versus  $>50\%$  (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). *Am J Cardiol*. 2014;114:988-996.
46. Uyar IS, Sahin V, Akpınar MB, et al. Decision making and results of coronary artery bypass grafting for patients with poor left ventricular function. *Heart Surg Forum*. 2013;16:e118-e124.
47. Zhang D, Lyu S, Song X, et al. Coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular systolic dysfunction: a meta-analysis. *Angiology*. 2017;68:19-28.
48. Orlandini A, Castellana N, Pascual A, et al. Myocardial viability for decision-making concerning revascularization in patients with left ventricular dysfunction and coronary artery disease: a meta-analysis of non-randomized and randomized studies. *Int J Cardiol*. 2015;182:494-499.
49. Wolff G, Dimitroulis D, Andreotti F, et al. Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis. *Circ Heart Fail*. 2017;10:e003255.
50. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med*. 2020;382:1395-1407.
51. Bangalore S, Maron DJ, Stone GW, et al. Routine revascularization versus initial medical therapy for stable ischemic heart disease: a systematic review and meta-analysis of randomized trials. *Circulation*. 2020;142:841-857.
52. Chacko L, P Howard J, Rajkumar C, et al. Effects of percutaneous coronary intervention on death and myocardial infarction stratified by stable and unstable coronary artery disease: a meta-analysis of randomized controlled trials. *Circ Cardiovasc Qual Outcomes*. 2020;13:e006363.
53. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med*. 2007;356:1503-1516.
54. Sedlis SP, Hartigan PM, Teo KK, et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease. *N Engl J Med*. 2015;373:1937-1946.
55. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. *J Am Coll Cardiol*. 2004;43:1743-1751.
56. Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation*. 2010;122:949-957.
57. Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation*. 2007;115:1082-1089.
58. TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic

- coronary-artery disease (TIME): a randomised trial. *Lancet*. 2001;358:951-957.
- 59.** Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med*. 1999;341:70-76.
- 60.** Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. *Circulation*. 2009;120:2529-2540.
- 61.** Gaudino M, Benedetto U, Fremes S, et al. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. *N Engl J Med*. 2018;378:2069-2077.
- 62.** Cao C, Manganas C, Horton M, et al. Angiographic outcomes of radial artery versus saphenous vein in coronary artery bypass graft surgery: a meta-analysis of randomized controlled trials. *J Thorac Cardiovasc Surg*. 2013;146:255-261.
- 63.** Gaudino M, Lorusso R, Rahouma M, et al. Radial artery versus right internal thoracic artery versus saphenous vein as the second conduit for coronary artery bypass surgery: a network meta-analysis of clinical outcomes. *J Am Heart Assoc*. 2019;8:e010839.
- 64.** Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. *J Am Coll Cardiol*. 2012;60:2481-2489.
- 65.** Valgimigli M, Gagnor A, Calabró P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. *Lancet*. 2015;385:2465-2476.
- 66.** Andò G, Capodanno D. Radial versus femoral access in invasively managed patients with acute coronary syndrome: a systematic review and meta-analysis. *Ann Intern Med*. 2015;163:932-940.
- 67.** Ferrante G, Rao SV, Jüni P, et al. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials. *J Am Coll Cardiol Interv*. 2016;9:1419-1434.
- 68.** Feldman DN, Swaminathan RV, Kaltenbach LA, et al. Adoption of radial access and comparison of outcomes to femoral access in percutaneous coronary intervention: an updated report from the national cardiovascular data registry (2007-2012). *Circulation*. 2013;127:2295-2306.
- 69.** Louvard Y, Benamer H, Garot P, et al. Comparison of transradial and transfemoral approaches for coronary angiography and angioplasty in octogenarians (the OCTOPLUS study). *Am J Cardiol*. 2004;94:1177-1180.
- 70.** Santas E, Bodi V, Sanchis J, et al. The left radial approach in daily practice. A randomized study comparing femoral and right and left radial approaches. *Rev Esp Cardiol*. 2009;62:482-490.
- 71.** Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. *N Engl J Med*. 2019;381:2032-2042.
- 72.** Hahn J-Y, Song YB, Oh J-H, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. *JAMA*. 2019;321:2428-2437.
- 73.** Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. *JAMA*. 2019;321:2414-2427.
- 74.** Kim B-K, Hong S-J, Cho Y-H, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. *JAMA*. 2020;323:2407-2416.
- 75.** Bittl JA, Baber U, Bradley SM, et al. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2016;68:1116-1139.
- 76.** Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. *J Am Coll Cardiol*. 2016;68:1082-1115.
- 77.** Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. *Heart*. 2010;96:662-667.
- 78.** Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. *J Am Coll Cardiol*. 2015;65:963-972.
- 79.** Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. *Lancet*. 2015;386:665-671.
- 80.** Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. *N Engl J Med*. 2019;381:1411-1421.
- 81.** Di Mario C, Mara S, Flavio A, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEPACOAT for cuLPrIt or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. *Int J Cardiovasc Intervent*. 2004;6:128-133.
- 82.** Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. *N Engl J Med*. 2013;369:1115-1123.
- 83.** Smits PC, Abdel-Wahab M, Neumann F-J, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. *N Engl J Med*. 2017;376:1234-1244.
- 84.** Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. *N Engl J Med*. 2017;377:2419-2432.
- 85.** Thiele H, Akin I, Sandri M, et al. One-year outcomes after PCI strategies in cardiogenic shock. *N Engl J Med*. 2018;379:1699-1710.
- 86.** Kolte D, Sardar P, Khera S, et al. Culprit vessel-only versus multivessel percutaneous coronary intervention in patients with cardiogenic shock complicating ST-segment-elevation myocardial infarction: a collaborative meta-analysis. *Circ Cardiovasc Interv*. 2017;10:e005582.
- 87.** Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med*. 2012;367:2375-2384.
- 88.** Farkouh ME, Domanski M, Dangas GD, et al. Long-term survival following multivessel revascularization in patients with diabetes: the FREEDOM follow-on study. *J Am Coll Cardiol*. 2019;73:629-638.
- 89.** Kamalesh M, Sharp TG, Tang XC, et al. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. *J Am Coll Cardiol*. 2013;61:808-816.
- 90.** Kappetein AP, Head SJ, Morice M-C, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. *Eur J Cardiothorac Surg*. 2013;43:1006-1013.
- 91.** Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. *Lancet*. 2018;391:939-948.
- 92.** Verma S, Farkouh ME, Yanagawa B, et al. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol*. 2013;1:317-328.
- 93.** Park S-J, Ahn J-M, Kim Y-H, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. *N Engl J Med*. 2015;372:1204-1212.
- 94.** Park D-W, Kim Y-H, Song HG, et al. Long-term outcome of stents versus bypass surgery in diabetic and nondiabetic patients with multivessel or left main coronary artery disease: a pooled analysis of 5775 individual patient data. *Circ Cardiovasc Interv*. 2012;5:467-475.
- 95.** Pandey A, McGuire DK, de Lemos JA, et al. Revascularization trends in patients with diabetes mellitus and multivessel coronary artery disease presenting with non-ST elevation myocardial infarction: insights from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry—Get With The Guidelines (NCDR ACTION Registry-GWTG). *Circ Cardiovasc Qual Outcomes*. 2016;9:197-205.
- 96.** Sedlis SP, Morrison DA, Lorin JD, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME

randomized trial and registry. *J Am Coll Cardiol*. 2002;40:1555-1566.

**97.** Milojevic M, Serruys PW, Sabik JF 3rd, et al. Bypass surgery or stenting for left main coronary artery disease in patients with diabetes. *J Am Coll Cardiol*. 2019;73:1616-1628.

**98.** Osnabrugge RL, Speir AM, Head SJ, et al. Performance of EuroSCORE II in a large US database: implications for transcatheter aortic valve implantation. *Eur J Cardiothorac Surg*. 2014;46:400-408.

**99.** Ad N, Holmes SD, Patel J, et al. Comparison of EuroSCORE II, original EuroSCORE, and the Society of Thoracic Surgeons risk score in cardiac surgery patients. *Ann Thorac Surg*. 2016;102:573-579.

**100.** Thielmann M, Mehmet A, Neuhäuser M, et al. Risk prediction and outcomes in patients with liver cirrhosis undergoing open-heart surgery. *Eur J Cardiothorac Surg*. 2010;38:592-599.

**101.** Modi A, Vohra HA, Barlow CW. Do patients with liver cirrhosis undergoing cardiac surgery have acceptable outcomes? *Interact Cardiovasc Thorac Surg*. 2010;11:630-634.

**102.** Reichart D, Rosato S, Nammias W, et al. Clinical frailty scale and outcome after coronary artery bypass grafting. *Eur J Cardiothorac Surg*. 2018;54:1102-1109.

**103.** Sündermann S, Dademasch A, Rastan A, et al. One-year follow-up of patients undergoing elective cardiac surgery assessed with the Comprehensive Assessment of Frailty test and its simplified form. *Interact Cardiovasc Thorac Surg*. 2011;13:119-123.

**104.** Sündermann SH, Dademasch A, Seifert B, et al. Frailty is a predictor of short- and mid-term mortality after elective cardiac surgery independently of age. *Interact Cardiovasc Thorac Surg*. 2014;18:580-585.

**105.** Afilalo J, Eisenberg MJ, Morin J-F, et al. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. *J Am Coll Cardiol*. 2010;56:1668-1676.

**106.** Afilalo J, Mottillo S, Eisenberg MJ, et al. Addition of frailty and disability to cardiac surgery risk scores identifies elderly patients at high risk of mortality or major morbidity. *Circ Cardiovasc Qual Outcomes*. 2012;5:222-228.

**107.** Lytwyn J, Stammers AN, Kehler DS, et al. The impact of frailty on functional survival in patients 1 year after cardiac surgery. *J Thorac Cardiovasc Surg*. 2017;154:1990-1999.

**108.** Sepehri A, Beggs T, Hassan A, et al. The impact of frailty on outcomes after cardiac surgery: a systematic review. *J Thorac Cardiovasc Surg*. 2014;148:3110-3117.

**109.** Ringaitienė D, Gineitytė D, Vicka V, et al. Impact of malnutrition on postoperative delirium development after on pump coronary artery bypass grafting. *J Cardiothorac Surg*. 2015;10:74.

**110.** Lomivorotov VV, Efremov SM, Boboshko VA, et al. Prognostic value of nutritional screening tools for patients scheduled for cardiac surgery. *Interact Cardiovasc Thorac Surg*. 2013;16:612-618.

**111.** Bayir H, Yildiz I. Malnutrition and adverse effects in cardiac surgery. *Thorac Cardiovasc Surg*. 2015;63:349-350.

**112.** O'Brien SM, Feng L, He X, et al. The Society of Thoracic Surgeons 2018 adult cardiac surgery risk models: part 2—statistical methods and results. *Ann Thorac Surg*. 2018;105:1419-1428.

**113.** Shahian DM, Jacobs JP, Badhwar V, et al. The Society of Thoracic Surgeons 2018 adult cardiac surgery risk models: part 1—background, design considerations, and model development. *Ann Thorac Surg*. 2018;105:1411-1418.

**114.** Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. *Eur J Cardiothorac Surg*. 2012;41:734-744. discussion 744-745.

**115.** Sianos G, Morel M-A, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. *Euro-Intervention*. 2005;1:219-227.

**116.** Garg S, Serruys PW, Silber S, et al. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial. *J Am Coll Cardiol Intv*. 2011;4:432-441.

**117.** Wykrzykowska JJ, Garg S, Girasis C, et al. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. *J Am Coll Cardiol*. 2010;56:272-277.

**118.** Cavalcante R, Sotomi Y, Mancione M, et al. Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. *Eur Heart J*. 2017;38:1969-1977.

---

**KEY WORDS** ACC/AHA Clinical Practice Guidelines, percutaneous coronary intervention (PCI), angioplasty, coronary artery bypass graft (CABG) surgery, myocardial infarction, cardiac surgery, stent(s), angiogram, angiography, percutaneous transluminal coronary angioplasty, coronary atherosclerosis, saphenous vein graft, internal mammary artery graft, internal thoracic artery graft, arterial graft, post-bypass, non-ST-segment-elevated myocardial infarction, vein graft lesions, myocardial revascularization, multivessel PCI, left ventricular dysfunction